Intensity Therapeutics, Inc. (INTS) stock

INTSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30

$3.28+0.19 (+6.15%)

Close on Nov 11, 2026Market cap $10.71MP/E –Yield –

Intensity Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Intensity Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?